SCM
CLRB icon

Silverarc Capital Management’s Cellectar Biosciences CLRB Stock Holding History

Silverarc Capital Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$894K Buy
+321,728
New +$900K 0.09% 70
2021
Q2 		– Sell
-2,021
Closed -$976K – 104
2021
Q1 		$976K Sell
2,021
-3,888
-66% -$2.31M 0.53% 54
2020
Q4 		$3.69M Buy
+5,909
New +$2.72M 2.14% 18

Other funds holding CLRB

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Silverarc Capital Management's CLRB Position: Q2 2026 in Review

Silverarc Capital Management opened a new position in Cellectar Biosciences (CLRB) in Q2 2026: 321,728 shares worth $894K. The stake represents 0.09% of the portfolio and ranks #70 among its holdings. This is a return to the name: Silverarc Capital Management previously reported a position in CLRB as recently as Q1 2021.

Silverarc Capital Management first reported a position in CLRB in Q4 2020 and has held it in 3 quarters since. The position peaked at $3.69M in Q4 2020. 29 funds tracked by Wall St. Rank hold CLRB as of Q2 2026.

  • Silverarc Capital Management held 321,728 shares of Cellectar Biosciences worth $894K as of Q2 2026.
  • Cellectar Biosciences was a new Silverarc Capital Management position in Q2 2026.
  • Cellectar Biosciences made up 0.09% of Silverarc Capital Management's portfolio in Q2 2026, its #70 holding.
  • Silverarc Capital Management first reported a position in Cellectar Biosciences in Q4 2020 and has held it in 3 quarters since.
  • Silverarc Capital Management's Cellectar Biosciences position peaked at $3.69M in Q4 2020.
  • 29 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.